Back to search

National and Kapodistrian University of Athens

H συμβολή της PET/CT στην επανασταδιοποίηση ασθενών με καρκίνο μαστού, αυξημένους καρκινικούς δείκτες και αρνητικά ή αμφίβολα ευρήματα στον συμβατικό απεικονιστικό έλεγχο

Abstract

dc:description

Recurrence of disease is quite frequent in patients with breast cancer, who have completed primary treatment. The prognosis and treatment planning depend mainly on the extent of the disease. Estimation of the true extent may sometimes be quite challenging. Progressive elevation of tumor markers is indicative of disease dissemination. However, in many cases, rising tumor markers may not be associated with abnormal findings in conventional imaging modalities. PET/CT, by combining morphological and metabolic information in the same examination, overcomes the limitation of anatomic imaging techniques and may contribute to the investigation of these patients, showing sites of abnormal metabolic activity, which correspond to active disease. The aim of our study was to evaluate the clinical impact of FDG PET/CT in restaging breast cancer patients with rising tumor markers and negative or equivocal findings in conventional imaging studies. We studied 46 patients with breast cancer of an average age of 57.6 years (ranging from 38 to 68 years). All patients were referred for an FDG PET/CT scan because of elevated tumor markers, without any other obvious clinical or laboratory sign of relapse. Conventional imaging studies results were either negative (29/46) or inconclusive (17/46). All patients underwent a whole body FDG PET/CT scan, in a combined PET/CT tomography. Findings were confirmed by an at least nine month follow-up, and when it was possible, final diagnosis was obtained by histopathology. In our study we found that FDG PET/CT may be a valuable tool for assessing patients with rising tumor markers and negative or equivocal findings in conventional imaging methods. In this group of patients it seems that although tumor markers may strongly indicate that there is an occult tumor recurrence, conventional imaging methods cannot estimate the true extent of the disease. In 34/46 patients, FDG PET/CT demonstrated sites of increased metabolic activity, indicating active disease. In 23/46 patients therapeutic approach and further clinical management was affected. FDG PET/CT was true positive in 33 patients, false positive in 1 patient, false negative in 5 patients and true negative in 7 patients. On the basis of our results FDG PET/CT in this population, has a sensitivity of 86.8%, specificity 87.5% and accuracy of 86.9%. The positive prognostic value is 97.1% and the negative prognostic value 58.3%. Clinical management was affected in 50% of these patients. False negative results were due to the small size of the lesions, and most of them are attributed to small liver lesions with a diameter of a few millimeters. There was also a case that proved to have osteoblastic bone deposits on a bone scan performed 2 months later. A false positive result was found and was attributed to the presence of inflammatory disease, with mediastinal node involvement. The fact that 50% of the population examined was managed differently after the PET/CT examination is the most important conclusion. It is also noteworthy that clinicians consider the results of this study reliable. The study has several limitations. First, only in a small number of cases, suspicious findings were confirmed by biopsy or surgery. In the majority of the cases conventional follow-up was mainly used to confirm FDG PET/CT results. Additionally, physicians were interviewed about the effect of PET/CT results on their therapeutic decisions only after the performance of PET/CT exam. Although FDG PET/CT seems to detect recurrences at an earlier stage, before morphologic abnormalities become evident, further investigation is needed to find out, whether there is an impact on survival in these women. The results of the present study indicate that hybrid study FDG PET/CT plays an important role in restaging breast cancer patients with rising tumor markers and negative or equivocal findings in conventional imaging techniques. Early diagnosis and assessment of the true extent of the disease can accurately be estimated by combining metabolic-functional and anatomical information in a single examination. FDG PET/CT is considered a sensitive and accurate method with a consequent clinical impact on further management in these patients.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Filippi, Vasiliki
  • Φιλιππή, Βασιλική

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40357

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Filippi, Vasiliki; Φιλιππή, Βασιλική. H συμβολή της PET/CT στην επανασταδιοποίηση ασθενών με καρκίνο μαστού, αυξημένους καρκινικούς δείκτες και αρνητικά ή αμφίβολα ευρήματα στον συμβατικό απεικονιστικό έλεγχο. National and Kapodistrian University of Athens, 2014. http://hdl.handle.net/10442/hedi/40357